Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Common Equity (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Common Equity for 5 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 116.04% to $29.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.7 million through Dec 2025, up 116.04% year-over-year, with the annual reading at $19.0 million for FY2025, N/A changed from the prior year.
  • Common Equity for Q4 2025 was $29.7 million at Neuphoria Therapeutics, up from $12.5 million in the prior quarter.
  • The five-year high for Common Equity was $40.8 million in Q2 2022, with the low at $12.5 million in Q3 2025.
  • Average Common Equity over 4 years is $22.6 million, with a median of $20.6 million recorded in 2023.
  • The sharpest move saw Common Equity crashed 45.65% in 2023, then skyrocketed 116.04% in 2025.
  • Over 4 years, Common Equity stood at $40.8 million in 2022, then plummeted by 45.65% to $22.2 million in 2023, then plummeted by 37.95% to $13.7 million in 2024, then surged by 116.04% to $29.7 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $29.7 million, $12.5 million, and $19.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.